CA3045665A1 - Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells - Google Patents
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells Download PDFInfo
- Publication number
- CA3045665A1 CA3045665A1 CA3045665A CA3045665A CA3045665A1 CA 3045665 A1 CA3045665 A1 CA 3045665A1 CA 3045665 A CA3045665 A CA 3045665A CA 3045665 A CA3045665 A CA 3045665A CA 3045665 A1 CA3045665 A1 CA 3045665A1
- Authority
- CA
- Canada
- Prior art keywords
- alternatives
- drug
- cells
- nucleic acid
- chimeric antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 505
- 239000003814 drug Substances 0.000 title claims abstract description 369
- 229940079593 drug Drugs 0.000 title claims abstract description 369
- 102000040945 Transcription factor Human genes 0.000 title claims description 231
- 108091023040 Transcription factor Proteins 0.000 title claims description 231
- 239000003446 ligand Substances 0.000 title claims description 102
- 210000004962 mammalian cell Anatomy 0.000 title claims description 44
- 108700019146 Transgenes Proteins 0.000 title claims description 21
- 230000035945 sensitivity Effects 0.000 title description 4
- 230000003190 augmentative effect Effects 0.000 title description 3
- 230000006698 induction Effects 0.000 title description 2
- 230000001939 inductive effect Effects 0.000 claims abstract description 477
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 395
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 239
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 181
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 181
- 108020001756 ligand binding domains Proteins 0.000 claims abstract description 175
- 239000002157 polynucleotide Substances 0.000 claims abstract description 146
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 145
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 145
- 125000006850 spacer group Chemical group 0.000 claims abstract description 125
- 238000000034 method Methods 0.000 claims abstract description 74
- 108091006106 transcriptional activators Proteins 0.000 claims abstract description 62
- 230000004068 intracellular signaling Effects 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 476
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 206
- 108090000623 proteins and genes Proteins 0.000 claims description 127
- 102000015694 estrogen receptors Human genes 0.000 claims description 118
- 108010038795 estrogen receptors Proteins 0.000 claims description 118
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims description 114
- 230000003915 cell function Effects 0.000 claims description 105
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 94
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 89
- 230000035772 mutation Effects 0.000 claims description 87
- 230000002103 transcriptional effect Effects 0.000 claims description 86
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 79
- 230000004044 response Effects 0.000 claims description 70
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 68
- 230000027455 binding Effects 0.000 claims description 67
- 229920001184 polypeptide Polymers 0.000 claims description 61
- 206010028980 Neoplasm Diseases 0.000 claims description 59
- 210000004698 lymphocyte Anatomy 0.000 claims description 59
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 59
- 108020004414 DNA Proteins 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 54
- -1 CE7 Proteins 0.000 claims description 50
- 239000013598 vector Substances 0.000 claims description 50
- 229960001603 tamoxifen Drugs 0.000 claims description 46
- 231100000252 nontoxic Toxicity 0.000 claims description 41
- 230000003000 nontoxic effect Effects 0.000 claims description 41
- 239000003550 marker Substances 0.000 claims description 40
- 239000012636 effector Substances 0.000 claims description 35
- 230000003612 virological effect Effects 0.000 claims description 34
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 33
- 229960002258 fulvestrant Drugs 0.000 claims description 33
- 238000006467 substitution reaction Methods 0.000 claims description 33
- 239000013603 viral vector Substances 0.000 claims description 33
- YHOXIEXEPIIKMD-UHFFFAOYSA-N 9a-[(4-chlorophenyl)methyl]-7-hydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-2,9-dihydro-1h-fluoren-3-one Chemical compound C1C2=CC(O)=CC=C2C2=C(C=3C=CC(OCCN4CCCCC4)=CC=3)C(=O)CCC21CC1=CC=C(Cl)C=C1 YHOXIEXEPIIKMD-UHFFFAOYSA-N 0.000 claims description 31
- 108700011259 MicroRNAs Proteins 0.000 claims description 30
- 239000002679 microRNA Substances 0.000 claims description 30
- 239000003687 estradiol congener Substances 0.000 claims description 29
- 108010002687 Survivin Proteins 0.000 claims description 27
- 239000002207 metabolite Substances 0.000 claims description 27
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 23
- 230000005764 inhibitory process Effects 0.000 claims description 23
- 239000002243 precursor Substances 0.000 claims description 23
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 21
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 21
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 21
- 208000002177 Cataract Diseases 0.000 claims description 21
- 206010010774 Constipation Diseases 0.000 claims description 21
- 206010012735 Diarrhoea Diseases 0.000 claims description 21
- 208000000059 Dyspnea Diseases 0.000 claims description 21
- 206010013975 Dyspnoeas Diseases 0.000 claims description 21
- 101150029707 ERBB2 gene Proteins 0.000 claims description 21
- 206010019233 Headaches Diseases 0.000 claims description 21
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 21
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 21
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 21
- 208000033830 Hot Flashes Diseases 0.000 claims description 21
- 206010060800 Hot flush Diseases 0.000 claims description 21
- 206010020772 Hypertension Diseases 0.000 claims description 21
- 102000003735 Mesothelin Human genes 0.000 claims description 21
- 108090000015 Mesothelin Proteins 0.000 claims description 21
- 208000000112 Myalgia Diseases 0.000 claims description 21
- 206010028813 Nausea Diseases 0.000 claims description 21
- 206010030113 Oedema Diseases 0.000 claims description 21
- 206010047700 Vomiting Diseases 0.000 claims description 21
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 21
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 21
- 238000011010 flushing procedure Methods 0.000 claims description 21
- 231100000869 headache Toxicity 0.000 claims description 21
- 208000013465 muscle pain Diseases 0.000 claims description 21
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 21
- 230000008693 nausea Effects 0.000 claims description 21
- 208000013220 shortness of breath Diseases 0.000 claims description 21
- 230000008673 vomiting Effects 0.000 claims description 21
- 208000016261 weight loss Diseases 0.000 claims description 21
- 230000004580 weight loss Effects 0.000 claims description 21
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims description 20
- 101710091045 Envelope protein Proteins 0.000 claims description 20
- 206010016807 Fluid retention Diseases 0.000 claims description 20
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 20
- 101710188315 Protein X Proteins 0.000 claims description 20
- 230000007423 decrease Effects 0.000 claims description 20
- 230000008030 elimination Effects 0.000 claims description 20
- 238000003379 elimination reaction Methods 0.000 claims description 20
- 206010016256 fatigue Diseases 0.000 claims description 20
- 230000011664 signaling Effects 0.000 claims description 20
- 230000006907 apoptotic process Effects 0.000 claims description 19
- 241000713666 Lentivirus Species 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 231100000433 cytotoxic Toxicity 0.000 claims description 17
- 230000001472 cytotoxic effect Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 241000702421 Dependoparvovirus Species 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 16
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 14
- 108700010039 chimeric receptor Proteins 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 12
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 102100038078 CD276 antigen Human genes 0.000 claims description 11
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 11
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 11
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 11
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 11
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 11
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 11
- 101710178046 Chorismate synthase 1 Proteins 0.000 claims description 10
- 101710152695 Cysteine synthase 1 Proteins 0.000 claims description 10
- 206010059866 Drug resistance Diseases 0.000 claims description 10
- 108010042634 F2A4-K-NS peptide Proteins 0.000 claims description 10
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 10
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 10
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 10
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 10
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 10
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 10
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 10
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 10
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 10
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 10
- 102100032831 Protein ITPRID2 Human genes 0.000 claims description 10
- 230000006052 T cell proliferation Effects 0.000 claims description 10
- 230000016396 cytokine production Effects 0.000 claims description 10
- 102000003675 cytokine receptors Human genes 0.000 claims description 10
- 108010057085 cytokine receptors Proteins 0.000 claims description 10
- 230000001461 cytolytic effect Effects 0.000 claims description 10
- 230000012010 growth Effects 0.000 claims description 10
- 108700012707 hepatitis C virus NS3 Proteins 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 238000012737 microarray-based gene expression Methods 0.000 claims description 10
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 10
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 10
- 230000004083 survival effect Effects 0.000 claims description 10
- 102000009410 Chemokine receptor Human genes 0.000 claims description 9
- 108050000299 Chemokine receptor Proteins 0.000 claims description 9
- 230000000840 anti-viral effect Effects 0.000 claims description 9
- 238000011319 anticancer therapy Methods 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000003284 homeostatic effect Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 102000000763 Survivin Human genes 0.000 claims 3
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims 2
- 102100035100 Transcription factor p65 Human genes 0.000 description 129
- 102000053602 DNA Human genes 0.000 description 45
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 24
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 18
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 10
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 10
- 102000001301 EGF receptor Human genes 0.000 description 9
- 108060006698 EGF receptor Proteins 0.000 description 9
- 102220342199 c.2T>A Human genes 0.000 description 9
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 6
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108700010908 HIV-1 proteins Proteins 0.000 description 3
- 101710113864 Heat shock protein 90 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 210000001723 extracellular space Anatomy 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 2
- 102000006754 Hepatocyte Nuclear Factor 1 Human genes 0.000 description 2
- 108010086512 Hepatocyte Nuclear Factor 1 Proteins 0.000 description 2
- 102000009824 Hepatocyte Nuclear Factor 1-alpha Human genes 0.000 description 2
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 2
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001071864 Lethrinus laticaudis Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433183P | 2016-12-12 | 2016-12-12 | |
| US62/433,183 | 2016-12-12 | ||
| PCT/US2017/065597 WO2018111763A1 (en) | 2016-12-12 | 2017-12-11 | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3045665A1 true CA3045665A1 (en) | 2018-06-21 |
Family
ID=62559136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3045665A Pending CA3045665A1 (en) | 2016-12-12 | 2017-12-11 | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11408005B2 (enExample) |
| EP (1) | EP3551197B1 (enExample) |
| JP (2) | JP7091357B2 (enExample) |
| CN (1) | CN110291200B (enExample) |
| AU (1) | AU2017375630B2 (enExample) |
| CA (1) | CA3045665A1 (enExample) |
| MX (1) | MX2019006631A (enExample) |
| WO (1) | WO2018111763A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| KR102508166B1 (ko) | 2014-04-10 | 2023-03-13 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 세포 면역요법을 위한 방법 및 조성물 |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| CN120154716A (zh) | 2018-01-22 | 2025-06-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| CN111936518A (zh) * | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| WO2019246563A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| JP2021530217A (ja) * | 2018-07-10 | 2021-11-11 | プレシゲン，インコーポレイテッド | Ｒｏｒ−１特異的キメラ抗原受容体およびその使用 |
| CA3110922A1 (en) * | 2018-08-28 | 2020-03-05 | Immunotech Biopharm Co., Ltd. | Improved therapeutic t cell |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| JP6821230B2 (ja) | 2019-02-04 | 2021-01-27 | 国立大学法人愛媛大学 | ＣＡＲライブラリおよびｓｃＦｖの製造方法 |
| EP3934666A1 (en) * | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| CA3140210A1 (en) * | 2019-03-13 | 2020-09-17 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Sodium fluorescein as a reversal agent for an anti-fluorescein car t cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers |
| WO2020219425A1 (en) * | 2019-04-25 | 2020-10-29 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias |
| KR20250095757A (ko) * | 2019-06-21 | 2025-06-26 | 카이트 파마 인코포레이티드 | TGF-β 수용체 및 이의 사용 방법 |
| JP7792335B2 (ja) * | 2019-12-12 | 2025-12-25 | センティ バイオサイエンシズ インコーポレイテッド | 細胞の調節されたアーマリングのための方法及び組成物 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| US20230242936A1 (en) * | 2020-05-14 | 2023-08-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Dual promoter systems |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| AU2021288464A1 (en) * | 2020-06-08 | 2023-01-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-CD171 chimeric antigen receptors |
| CN111848819A (zh) * | 2020-07-31 | 2020-10-30 | 广东昭泰体内生物医药科技有限公司 | 一种靶向msln的嵌合抗原受体及其应用 |
| AU2021358524A1 (en) * | 2020-10-09 | 2023-06-01 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods and compositions comprising pd1 chimeric polypeptides |
| EP4259648A4 (en) * | 2020-12-08 | 2025-03-26 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Chimeric anti-EGFR antigen receptors |
| WO2022174035A2 (en) * | 2021-02-12 | 2022-08-18 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Activity-inducible fusion proteins having a heat shock protein 90 binding domain |
| EP4323410A4 (en) * | 2021-04-15 | 2025-03-26 | The Regents of the University of Colorado, a body corporate | Compositions and methods for the preparation and use of cell-based immunotherapies against tumors |
| EP4341283A4 (en) * | 2021-05-14 | 2025-06-25 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Activity-inducible fusion proteins with a transcription factor and a heat shock protein 90 binding domain |
| CN116514982B (zh) * | 2021-12-29 | 2023-12-19 | 华道(上海)生物医药有限公司 | 一种抗IL13Ra2的纳米抗体及其应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| US20020111474A1 (en) | 1990-12-14 | 2002-08-15 | Capon Daniel J. | Chimeric chains for receptor-associated signal transduction pathways |
| JPH07507278A (ja) | 1992-06-01 | 1995-08-10 | ニューイングランド メディカル センター ホスピタルズ インク | Ｃｄ４３キメラ分子による細胞間相互作用の阻害 |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US6133027A (en) * | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| GB0015119D0 (en) * | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| EP1297168A2 (en) | 2000-07-03 | 2003-04-02 | Gala Design, Inc. | Expression vectors |
| PL206701B1 (pl) | 2001-03-07 | 2010-09-30 | Merck Patent Gmbh | Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| WO2002097099A1 (en) | 2001-05-29 | 2002-12-05 | Valentis, Inc. | Regulated expression of ghrh |
| DE60228082D1 (de) * | 2001-05-31 | 2008-09-18 | Novartis Ag | Nten und neue liganden und pharmazeutische zusammensetzungen |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| MXPA04009809A (es) | 2002-04-11 | 2004-12-13 | Amgen Inc | Moleculas de tirosina cinasa del receptor her-2 y uso de las mismas. |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US20060160090A1 (en) | 2003-04-11 | 2006-07-20 | Macina Robert A | Composition splice variants and methods relating to cancer specific genes and proteins |
| WO2005017102A2 (en) | 2003-05-30 | 2005-02-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| EP1649020B1 (en) | 2003-07-21 | 2017-01-11 | MSD Italia S.r.l. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| EP1680447A2 (en) | 2003-10-24 | 2006-07-19 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Orthogonal gene switches |
| WO2005062881A2 (en) | 2003-12-24 | 2005-07-14 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| US7935510B2 (en) * | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| MX2008008046A (es) | 2005-12-21 | 2009-03-04 | Micromet Ag | Moleculas de epha2-bite y usos de las mismas. |
| US8148129B2 (en) * | 2006-06-30 | 2012-04-03 | The Regents Of The University Of California | Generation of potent dominant negative transcriptional inhibitors |
| WO2008012237A1 (en) | 2006-07-24 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Multi-antigen construct and uses thereof |
| US7709253B2 (en) | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| JP5779090B2 (ja) | 2008-04-09 | 2015-09-16 | マックスサイト インコーポレーティッド | 新規に単離された細胞の治療組成物の操作および送達 |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| ES2706899T3 (es) | 2008-09-26 | 2019-04-01 | Tocagen Inc | Vectores de terapia génica y citosina desaminasas |
| US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
| WO2010141543A1 (en) | 2009-06-02 | 2010-12-09 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
| US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
| PT2496698T (pt) | 2009-11-03 | 2019-04-18 | Hope City | Recetor de fator de crescimento epidermal truncado (egfrt) para seleção de células t transduzidas |
| JP5285678B2 (ja) | 2010-06-18 | 2013-09-11 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信方法及びコアネットワーク装置 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| MX2013008376A (es) | 2011-01-18 | 2013-08-12 | Univ Pennsylvania | Composiciones y metodos para el tratamiento de cancer. |
| JP6203705B2 (ja) | 2011-03-23 | 2017-09-27 | フレッド ハッチンソン キャンサー リサーチ センター | 細胞免疫療法のための方法および組成物 |
| CN103502439B (zh) | 2011-04-13 | 2016-10-12 | 因缪尼卡姆股份公司 | 用于抗原特异性t细胞增殖的方法 |
| EA201400046A1 (ru) | 2011-06-22 | 2014-07-30 | Ф. Хоффманн-Ля Рош Аг | Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов |
| DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| ITRM20120058A1 (it) | 2012-02-20 | 2013-08-21 | Pisanelli Giovanni Codacci | Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione |
| EP3747898B1 (en) | 2012-02-22 | 2023-03-15 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| HK1203393A1 (en) | 2012-04-11 | 2015-10-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| WO2013177533A1 (en) | 2012-05-25 | 2013-11-28 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| WO2013181440A1 (en) | 2012-05-30 | 2013-12-05 | Baylor College Of Medicine | Supercoiled minivectors as a tool for dna repair, alteration and replacement |
| EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
| WO2013180287A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電気株式会社 | スイッチングシステム、ラインカード、スイッチカード、ｆｄｂ学習方法、ｆｄｂ学習調停方法及びプログラム |
| PH12019550223A1 (en) | 2012-08-20 | 2024-02-19 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| WO2014039044A1 (en) | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
| JP6441802B2 (ja) | 2012-10-02 | 2018-12-19 | メモリアル スローン ケタリング キャンサー センター | 免疫療法のための組成物および方法 |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| WO2014138704A1 (en) | 2013-03-07 | 2014-09-12 | Baylor College Of Medicine | Targeting cd138 in cancer |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| ES2832586T3 (es) | 2013-11-21 | 2021-06-10 | Autolus Ltd | Célula |
| US10239948B2 (en) | 2013-12-20 | 2019-03-26 | Cellectis | Method of engineering multi-input signal sensitive T cell for immunotherapy |
| CN113307880B (zh) | 2014-01-13 | 2025-07-04 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| CN106163547A (zh) | 2014-03-15 | 2016-11-23 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| KR102508166B1 (ko) * | 2014-04-10 | 2023-03-13 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 세포 면역요법을 위한 방법 및 조성물 |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| CN108779160A (zh) | 2016-02-05 | 2018-11-09 | 希望之城公司 | 施用工程化t细胞以治疗中枢神经系统中的癌症 |
| US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
-
2017
- 2017-12-11 US US16/467,015 patent/US11408005B2/en active Active
- 2017-12-11 AU AU2017375630A patent/AU2017375630B2/en active Active
- 2017-12-11 EP EP17881828.2A patent/EP3551197B1/en active Active
- 2017-12-11 MX MX2019006631A patent/MX2019006631A/es unknown
- 2017-12-11 JP JP2019551508A patent/JP7091357B2/ja active Active
- 2017-12-11 CA CA3045665A patent/CA3045665A1/en active Pending
- 2017-12-11 WO PCT/US2017/065597 patent/WO2018111763A1/en not_active Ceased
- 2017-12-11 CN CN201780086283.8A patent/CN110291200B/zh active Active
-
2022
- 2022-06-15 JP JP2022096360A patent/JP7392043B2/ja active Active
- 2022-06-20 US US17/807,774 patent/US20220411805A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220411805A1 (en) | 2022-12-29 |
| MX2019006631A (es) | 2019-11-12 |
| WO2018111763A1 (en) | 2018-06-21 |
| CN110291200B (zh) | 2024-05-14 |
| US20200181624A1 (en) | 2020-06-11 |
| AU2017375630A1 (en) | 2019-06-13 |
| EP3551197A1 (en) | 2019-10-16 |
| JP2020500563A (ja) | 2020-01-16 |
| EP3551197A4 (en) | 2020-10-28 |
| EP3551197B1 (en) | 2023-11-22 |
| WO2018111763A9 (en) | 2018-07-19 |
| AU2017375630B2 (en) | 2023-12-21 |
| JP7091357B2 (ja) | 2022-06-27 |
| JP2022130485A (ja) | 2022-09-06 |
| JP7392043B2 (ja) | 2023-12-05 |
| US11408005B2 (en) | 2022-08-09 |
| CN110291200A (zh) | 2019-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220411805A1 (en) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells | |
| JP7093385B2 (ja) | 薬物制御による導入遺伝子の発現 | |
| HK40061934A (en) | Drug related transgene expression | |
| HK1233274B (en) | Drug related transgene expression | |
| BR112016023513B1 (pt) | Sistema para expressão induzível de um receptor de antígeno quimérico, método in vitro para a preparação de sistema e uso de uma célula hospedeira compreendendo um sistema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20221202 |
|
| EEER | Examination request |
Effective date: 20221202 |
|
| EEER | Examination request |
Effective date: 20221202 |
|
| EEER | Examination request |
Effective date: 20221202 |